Advertisement
Advertisement

SYRE

SYRE logo

Spyre Therapeutics, Inc. Common Stock

75.05
USD
Sponsored
+1.95
+2.66%
May 08, 16:00 UTC -4
Closed
exchange

After-Market

75.05

0.00
+0.01%

Spyre Therapeutics, Inc. Common Stock Profile

About

Spyre Therapeutics is a biotechnology company which aims to create inflammatory bowel disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches for patient selection. Spyre Therapeutics, formerly known as Aeglea BioTherapeutics Inc., is based in WALTHAM, Mass.

Info & Links

CEO

Cameron Turtle, D.Phil

Headquarters

221 CRESCENT STREET,BUILDING 23, SUITE 105
WALTHAM, MA 02453, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

https://www.spyre.com

Auditor

PricewaterhouseCoopers LLP

Share holders

24

Employees

102

Spyre Therapeutics, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

6.52B

Enterprise Value

6.43B

Enterprise Value/EBITDA(ttm)

-30.69

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

7.18

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-41.79%

Return on Invested Capital(ttm)

-28.53%

Return on Assets(ttm)

-25.97%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-209.56M

Net Income Available to Common(ttm)

-155.20M

Diluted EPS(ttm)

-2.08

Share Statistics

Beta (5Y Monthly)

2.93

52-Week Change

483.55%

S&P 500 52-Week Change

26.60%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

78.54M

Dividend Yield

0.00%

Float4

66.42M

% Held by Insiders

15.43%

% Held by Institutions

80.39%

Balance Sheet

Total Cash(mrq)

756.53M

Total Cash Per Share(mrq)

9.63

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

13.25%

Quick Ratio(mrq)

13.25%

Book Value Per Share(mrq)

9.15

Cash Flow

Operating Cash Flow Per Share(ytd)

-2.64

Free Cash Flow(ytd)

-169.25M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement